Healthcare Tech Stocks Tied To Prescription Waste And Digital Care Growth

Medicine worth an estimated £480m is reportedly wasted each year in England, which puts a harsh spotlight on how prescriptions are written, supplied and used. That kind of leakage can reshape where money flows across healthcare technology. Investors watching digital health and pharmacy platforms may not want to sit this out. This article looks at three Healthcare Technology Providers stocks exposed to this debate and explains why they might matter for your watchlist.

The stocks covered below are only a small sample, and the full screen surfaced 7 more Healthcare Technology Providers with equally compelling narratives that are not discussed in this article. If you want to identify higher conviction ideas in this space, go straight to the Healthcare Technology Providers screener.

OptimizeRx (OPRX)

Overview: OptimizeRx is a US digital healthcare technology company that helps pharmaceutical brands and healthcare providers deliver targeted messages and financial support offers to patients through electronic health records, pharmacy alerts, connected TV and other digital channels at the point of care.

Operations: OptimizeRx generates all of its roughly US$107 million in revenue from internet software and services in the United States.

Market Cap: US$126 million

OptimizeRx sits in the middle of how prescriptions are written and filled, which matters when regulators are looking harder at medicine waste and adherence. Its platform supports targeted messaging and copay programs inside prescribing workflows, and the recent launch of tools like CopayCue and an AI-powered audience builder indicates that management is focused on helping drug manufacturers fine tune who receives which offer and when. Analysts have published expectations for future earnings, yet the stock currently trades at a discount to both selected peers and those published price targets, while the company uses debt facilities and potential buybacks to reshape its capital structure. Investors may wish to consider the company’s exposure to a concentrated pharma customer base and higher balance sheet risk, as these factors could reduce potential benefits if growth expectations are not met.

OptimizeRx looks like a classic case of a healthcare tech stock where sentiment and price are out of sync. Before you decide how that gap closes, scan the DCF valuation analysis for OptimizeRx that could change how you view its risk and capital choices.

Build your own healthcare tech shortlist

OptimizeRx and the other two stocks in this article all came from the same screener, which is where the real opportunity starts for you. Use our flexible Screener to blend filters across valuation, earnings, balance sheet and risks, or jump straight into our ready made Investing Ideas for curated stock shortlists that fit different investing styles.

Phreesia (PHR)

Overview: Phreesia runs a SaaS and payments platform that handles digital check in, intake forms, payments and patient communication for healthcare providers, as well as targeted engagement programs for life sciences companies and public sector organisations in the United States and Canada.

Operations: Phreesia generates all of its roughly US$496 million in revenue from Technology Solutions.

Market Cap: US$706 million

Phreesia sits squarely in the middle of the medicine waste debate because its tools digitise intake, payments and prescription related workflows, which helps providers tighten how and when medicines are prescribed and paid for. That aligns closely with current pressure to cut the estimated £480m of wasted drugs in England each year and could support demand for its AI based appointment optimisation, smart answering and medication adherence modules. At the same time, you need to weigh that earnings are still priced on a high P/E, and the company relies heavily on external funding. If regulators and payers keep pushing for cleaner prescription journeys, the real question is how much of that value Phreesia can capture.

Phreesia’s high P/E and heavy external funding make the stock look finely balanced, which is exactly why a fresh read of the analyst forecasts for Phreesia could change how you see where the real pressure point is next

Hydreight Technologies (TSXV:NURS)

Overview: Hydreight Technologies runs a US based digital health platform that lets patients book confidential mobile and virtual medical and wellness services, while also supporting clinics and practitioners with telemedicine tools, staffing, training, marketing and an online pharmacy network across all 50 states.

Operations: Hydreight Technologies generates about CA$27.8 million from virtual direct to consumer healthcare, CA$20.4 million from mobile medical services and CA$7.5 million from physical healthcare locations.

Market Cap: CA$205 million

Hydreight Technologies sits at the intersection of the push toward at home, tech enabled care and the surge in interest in GLP 1 and peptide based therapies, which are core to its VSDHOne platform and nationwide pharmacy network. The stock has just tipped into profitability, revenue growth forecasts are very strong, and analysts see room between today’s share price and their targets. However, the P/E is already rich and the business leans on higher risk external funding and ongoing share dilution. If regulators tighten rules on virtual care or compounded peptides, that could pressure margins and growth. For investors, the appeal is a fast scaling model with high quality earnings potential, but with regulatory and funding risks that need close attention.

Hydreight Technologies looks like a fast scaling at home care story that many investors have only half priced in. Before you decide how sustainable that trajectory really is, scan the analyst forecasts for Hydreight Technologies and see what the market might be missing next.

Seeking Fresh Alternatives Before Others

Some of the most interesting stocks often move from quiet to crowded quickly. Use these fresh shortlists before the crowd catches on and pricing momentum changes, then act based on your own judgment.

• Spot companies with strong cash generation and robust balance sheets before they get fully priced by checking the 49 high quality undervalued stocks while it still feels under the radar.
• Review structural trends in automation and smart manufacturing by looking at the hand picked 36 robotics and automation stocks before these stories are widely reflected in market sentiment.
• Explore potential shifts in global energy infrastructure by scanning the curated 89 nuclear energy infrastructure stocks while it may still offer a broader range of entry points.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com